liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Improving the efficacy of cancer immunotherapy
St Georges University.
St Georges University.
Leiden University.
Argos Therapeut.
Visa övriga samt affilieringar
2009 (Engelska)Ingår i: EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, Vol. 45, nr 8, s. 1424-1431Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.

Ort, förlag, år, upplaga, sidor
2009. Vol. 45, nr 8, s. 1424-1431
Nyckelord [en]
Immunotherapy, Cancer vaccine, Clinical response, Immunological monitoring, Combination therapy, Immunosupression, End-points, Surrogate end-points
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-19404DOI: 10.1016/j.ejca.2008.12.017OAI: oai:DiVA.org:liu-19404DiVA, id: diva2:224925
Tillgänglig från: 2009-06-23 Skapad: 2009-06-22 Senast uppdaterad: 2010-05-24

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext
Av organisationen
Onkologiska kliniken US
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 66 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf